Despite an arsenal of medicines and revascularization options, millions of individuals experience acute and chronic anginal symptoms daily. Imperative upon physicians is a responsibility not only to extend life and prevent major life-threatening complications but also to improve the quality of life. To that end, clinical trials of new treatment modalities for ischemic heart disease and the adoption of new therapies into practice should weigh these twin goals.
Ranolazine represents a novel type of antianginal therapy thought to reduce symptoms by blocking intracellular sodium and calcium overload accompanying myocardial ischemia.1- 2 Randomized trials demonstrated that ranolazine was effective in reducing angina symptoms and increasing exercise time to angina or ST-segment depression when compared with standard therapeutic agents, such as atenolol, diltiazem, and amlodipine without hemodynamic adverse effects.1,3- 4 However, these trials were limited in size and duration, and were not powered to assess the effect of ranolazine on major clinical cardiovascular end points such as death or myocardial infarction (MI). In addition, safety concerns were raised that ranolazine administration prolongs the QT interval and may have caused rare cases of unexplained syncope.1 Although the US Food and Drug Administration ultimately approved ranolazine for US marketing in 2006, the agency also suggested further evaluation to address these lingering safety concerns.5
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Thank you for submitting a comment on this article. It will be reviewed by JAMA editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
The Rational Clinical Examination
Evidence Summary and Review 2
The Rational Clinical Examination
Multivariate Findings for ACI Syndromes
All results at
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.